WithdrawnNCT06735079
A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)
Medication studyAges 18–65Italy + SwitzerlandDepression
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Milan and 1 more locationSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: December 27, 2024
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- MGGM LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Switzerland, Italy
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06735079
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 As Adjunctive Treatment for Major Depressive Disorder (MDD)
Recruitment & locations
WithdrawnMilan, Italy · Lugano, Switzerland
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is MGGM LLC.
Does this study involve medication?
Yes. The study involves medication, including REL1017 (esmethadone HCI) (active drug) and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as withdrawn.
